Crinetics Pharmaceuticals Inc
CRNX45.280USD
+0.490+1.09%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.28BMarket Cap
LossP/E TTM
More Details of Crinetics Pharmaceuticals Inc Company
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Crinetics Pharmaceuticals Inc Info
Ticker SymbolCRNX
Company nameCrinetics Pharmaceuticals Inc
IPO dateJul 18, 2018
CEOStruthers (R. Scott)
Number of employees437
Security typeOrdinary Share
Fiscal year-endJul 18
Address6055 Lusk Blvd.
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18584506464
Websitehttps://www.crinetics.com/
Ticker SymbolCRNX
IPO dateJul 18, 2018
CEOStruthers (R. Scott)
Company Executives of Crinetics Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
117.28K
+18000.00%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6900.00%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
+52000.00%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+6900.00%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
16.30K
+6900.00%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+6900.00%
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+6900.00%
Dr. R. Scott Struthers, Ph.D.
Dr. R. Scott Struthers, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. Jeff Knight
Mr. Jeff Knight
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
117.28K
+18000.00%
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6900.00%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
+52000.00%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+6900.00%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
16.30K
+6900.00%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+6900.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.21%
The Vanguard Group, Inc.
9.60%
Wellington Management Company, LLP
8.83%
BlackRock Institutional Trust Company, N.A.
7.01%
Driehaus Capital Management, LLC
6.83%
Other
54.51%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.21%
The Vanguard Group, Inc.
9.60%
Wellington Management Company, LLP
8.83%
BlackRock Institutional Trust Company, N.A.
7.01%
Driehaus Capital Management, LLC
6.83%
Other
54.51%
Shareholder Types
Shareholders
Proportion
Investment Advisor
53.07%
Investment Advisor/Hedge Fund
43.70%
Hedge Fund
14.23%
Individual Investor
2.04%
Venture Capital
2.01%
Research Firm
1.94%
Private Equity
1.16%
Bank and Trust
0.57%
Pension Fund
0.44%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
525
110.25M
122.53%
+10.44K
2025Q3
543
110.25M
126.46%
+2.35M
2025Q2
527
106.83M
124.47%
+1.78M
2025Q1
508
105.21M
122.53%
-8.81M
2024Q4
492
102.43M
107.05%
+15.47M
2024Q3
460
87.33M
121.15%
+1.87M
2024Q2
441
84.74M
119.85%
+1.98M
2024Q1
399
82.75M
110.72%
-4.21M
2023Q4
366
73.18M
119.64%
+1.80M
2023Q3
342
72.45M
96.67%
+14.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
12.54M
13.21%
+112.83K
+0.91%
Sep 30, 2025
The Vanguard Group, Inc.
9.15M
9.64%
-86.00K
-0.93%
Sep 30, 2025
Wellington Management Company, LLP
8.38M
8.83%
+2.57M
+44.34%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.65M
7.01%
+153.26K
+2.36%
Sep 30, 2025
Driehaus Capital Management, LLC
6.48M
6.83%
+81.59K
+1.27%
Sep 30, 2025
Farallon Capital Management, L.L.C.
5.77M
6.08%
+145.00K
+2.58%
Sep 30, 2025
T. Rowe Price Associates, Inc.
5.20M
5.48%
-289.29K
-5.27%
Sep 30, 2025
EcoR1 Capital, LLC
4.29M
4.52%
--
--
Sep 30, 2025
Janus Henderson Investors
3.86M
4.07%
+448.47K
+13.15%
Sep 30, 2025
Paradigm BioCapital Advisors LP
2.55M
2.69%
+207.22K
+8.84%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
3.24%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.92%
Tema Heart & Health ETF
1.9%
ALPS Medical Breakthroughs ETF
1.79%
iShares U.S. Pharmaceuticals ETF
1.51%
First Trust Multi-Manager Small Cap Opportunities ETF
1.31%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
ProShares Ultra Nasdaq Biotechnology
0.52%
Invesco Nasdaq Biotechnology ETF
0.4%
iShares Biotechnology ETF
0.34%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.24%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.92%
Tema Heart & Health ETF
Proportion1.9%
ALPS Medical Breakthroughs ETF
Proportion1.79%
iShares U.S. Pharmaceuticals ETF
Proportion1.51%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion1.31%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.92%
ProShares Ultra Nasdaq Biotechnology
Proportion0.52%
Invesco Nasdaq Biotechnology ETF
Proportion0.4%
iShares Biotechnology ETF
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
